A Review of Therapeutic Antibodies in Breast Cancer

Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug conjugated, or bispecific ones, researchers, ha...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy & pharmaceutical sciences 2021, Vol.24 (3), p.363-380
Main Authors: Eini, Maryam, Zainodini, Nahid, Montazeri, Hamed, Mirzabeigi, Parastoo, Tarighi, Parastoo
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacology
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - pharmacology
B7-H1 Antigen - immunology
Breast Neoplasms - drug therapy
Breast Neoplasms - immunology
Female
Humans
Programmed Cell Death 1 Receptor - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer. By developing different types of monoclonal antibodies such as humanized, drug conjugated, or bispecific ones, researchers, have achieved remarkable success in treating several complicated and challenging diseases, targeting specific antigens or receptors makes monoclonal antibodies the right choice to inhibit signaling pathways like programmed death-ligand 1 (PD-L1) or programmed death1 (PD-1) and changing cell behavior. As one of the most common types of malignancies among women, breast cancer is one of the most critical conditions which different types of monoclonal antibodies were designed and produced to treat. Therefore, we reviewed these antibodies in breast cancer, their targets, and their efficacy and toxicity, with more focus on recent PD-L1or PD-1 inhibitor antibodies in breast cancer and beyond.
ISSN:1482-1826
1482-1826
DOI:10.18433/jpps31864